tesaglitazar (BioDeep_00000779437)
代谢物信息卡片
tesaglitazar
化学式: C20H24O7S (408.1242674)
中文名称: 替格列扎
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
InChI: InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D01274
- PubChem: 208901
- DrugBank: DB06536
- DrugBank: DB07399
- ChEMBL: CHEMBL282686
- CAS: 251565-85-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M Hofmann, Patrick J Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D DiMarchi, Matthias H Tschöp, Brian Finan, Timo D Müller. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice.
Nature metabolism.
2022 08; 4(8):1071-1083. doi:
10.1038/s42255-022-00617-6. [PMID: 35995995] - Victoria Osinski, Dustin K Bauknight, Siva Sai Krishna Dasa, Matthew J Harms, Tobias Kroon, Melissa A Marshall, James C Garmey, Anh T Nguyen, Julia Hartman, Aditi Upadhye, Prasad Srikakulapu, Andrea Zhou, Gavin O'Mahony, Alexander L Klibanov, Kimberly A Kelly, Jeremie Boucher, Coleen A McNamara. In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects.
Theranostics.
2020; 10(2):585-601. doi:
10.7150/thno.36572. [PMID: 31903139] - Charikleia Kalliora, Ioannis D Kyriazis, Shin-Ichi Oka, Melissa J Lieu, Yujia Yue, Estela Area-Gomez, Christine J Pol, Ying Tian, Wataru Mizushima, Adave Chin, Diego Scerbo, P Christian Schulze, Mete Civelek, Junichi Sadoshima, Muniswamy Madesh, Ira J Goldberg, Konstantinos Drosatos. Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
JCI insight.
2019 08; 5(?):. doi:
10.1172/jci.insight.129556. [PMID: 31393858] - Yuri A Blednov, Jillian M Benavidez, Mendy Black, Laura B Ferguson, Grant L Schoenhard, Alison M Goate, Howard J Edenberg, Leah Wetherill, Victor Hesselbrock, Tatiana Foroud, R Adron Harris. Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Alcoholism, clinical and experimental research.
2015 Jan; 39(1):136-45. doi:
10.1111/acer.12610. [PMID: 25516156] - Alexandra Rogue, Sébastien Anthérieu, Aurore Vluggens, Thierry Umbdenstock, Nancy Claude, Catherine de la Moureyre-Spire, Richard J Weaver, André Guillouzo. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Toxicology and applied pharmacology.
2014 Apr; 276(1):73-81. doi:
10.1016/j.taap.2014.02.001. [PMID: 24534255] - Bu-chun Zhang, Xian-kai Li, Wen-liang Che, Wei-ming Li, Lei Hou, Yi-dong Wei, Ya-wei Xu. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
Zhonghua xin xue guan bing za zhi.
2013 Feb; 41(2):143-9. doi:
NULL. [PMID: 23710746] - Yoshihiro Shibata, Katsuji Kagechika, Mitsuhiro Yamaguchi, Hideo Kubo, Hiroyuki Usui. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Bioorganic & medicinal chemistry letters.
2012 Dec; 22(23):7075-9. doi:
10.1016/j.bmcl.2012.09.092. [PMID: 23084275] - J P H Wilding. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Diabetes, obesity & metabolism.
2012 Nov; 14(11):973-82. doi:
10.1111/j.1463-1326.2012.01601.x. [PMID: 22443197] - Bengt Hamrén, K Peter Ohman, Maria K Svensson, Mats O Karlsson. Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.
Journal of clinical pharmacology.
2012 Sep; 52(9):1317-27. doi:
10.1177/0091270011416937. [PMID: 22045829] - Heng Wei, Chunxiu Hu, Mei Wang, Anita M van den Hoek, Theo H Reijmers, Suzan Wopereis, Jildau Bouwman, Raymond Ramaker, Henrie A A J Korthout, Marco Vennik, Thomas Hankemeier, Louis M Havekes, Renger F Witkamp, Elwin R Verheij, Guowang Xu, Jan van der Greef. Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.
PloS one.
2012; 7(1):e30332. doi:
10.1371/journal.pone.0030332. [PMID: 22291936] - Renée Deehan, Pia Maerz-Weiss, Natalie L Catlett, Guido Steiner, Ben Wong, Matthew B Wright, Gil Blander, Keith O Elliston, William Ladd, Maria Bobadilla, Jacques Mizrahi, Carolina Haefliger, Alan Edgar. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
PloS one.
2012; 7(4):e35012. doi:
10.1371/journal.pone.0035012. [PMID: 22514701] - Nalinee Poolsup, Naeti Suksomboon, Wanwaree Setwiwattanakul. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.
ISRN endocrinology.
2012; 2012(?):798146. doi:
10.5402/2012/798146. [PMID: 22619731] - Preeti Raval, Mukul Jain, Amitgiri Goswami, Sujay Basu, Archana Gite, Atul Godha, Harikishore Pingali, Saurin Raval, Suresh Giri, Dinesh Suthar, Maanan Shah, Pankaj Patel. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Bioorganic & medicinal chemistry letters.
2011 May; 21(10):3103-9. doi:
10.1016/j.bmcl.2011.03.020. [PMID: 21450468] - Alexandra Rogue, Carine Lambert, Rozenn Jossé, Sebastien Antherieu, Catherine Spire, Nancy Claude, André Guillouzo. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes.
PloS one.
2011 Apr; 6(4):e18816. doi:
10.1371/journal.pone.0018816. [PMID: 21533120] - Salvatore Salomone. Pleiotropic effects of glitazones: a double edge sword?.
Frontiers in pharmacology.
2011; 2(?):14. doi:
10.3389/fphar.2011.00014. [PMID: 21687509] - Robert A Ettlin, Junji Kuroda, Stephanie Plassmann, Makoto Hayashi, David E Prentice. Successful drug development despite adverse preclinical findings part 2: examples.
Journal of toxicologic pathology.
2010 Dec; 23(4):213-34. doi:
10.1293/tox.23.213. [PMID: 22272032] - Jakob Ribbing, Bengt Hamrén, Maria K Svensson, Mats O Karlsson. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Journal of clinical pharmacology.
2010 Aug; 50(8):861-72. doi:
10.1177/0091270009349711. [PMID: 20484615] - Jie Liao, Zohreh Soltani, Philip Ebenezer, Angel A Isidro-Carrión, Rubin Zhang, Arshad Asghar, Erwin Aguilar, Joseph Francis, Xuejiao Hu, León Ferder, Efrain Reisin. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Nephron. Experimental nephrology.
2010; 114(2):e61-8. doi:
10.1159/000254567. [PMID: 19887847] - Elena Ovcharenko, Michael K Hansen, Ilia Goltsman, Niroz Abu-Saleh, Zaid Abassi, Kathryn Walsh, Gino Miele, Giora Z Feuerstein, Joseph Winaver. Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.
Nephron. Physiology.
2010; 115(3):p21-30. doi:
10.1159/000314541. [PMID: 20460939] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - J W A van der Hoorn, J W Jukema, L M Havekes, E Lundholm, G Camejo, P C N Rensen, H M G Princen. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
British journal of pharmacology.
2009 Apr; 156(7):1067-75. doi:
10.1111/j.1476-5381.2008.00109.x. [PMID: 19220285] - Harikishore Pingali, Mukul Jain, Shailesh Shah, Sujay Basu, Pankaj Makadia, Amitgiri Goswami, Pandurang Zaware, Pravin Patil, Atul Godha, Suresh Giri, Ashish Goel, Megha Patel, Harilal Patel, Pankaj Patel. Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Bioorganic & medicinal chemistry letters.
2008 Oct; 18(20):5586-90. doi:
10.1016/j.bmcl.2008.08.112. [PMID: 18805005] - B Hamrén, E Björk, M Sunzel, Mo Karlsson. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.
Clinical pharmacology and therapeutics.
2008 Aug; 84(2):228-35. doi:
10.1038/clpt.2008.2. [PMID: 18388881] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Bengt Hamrén, Hans Ericsson, Ola Samuelsson, Mats O Karlsson. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.
British journal of clinical pharmacology.
2008 Jun; 65(6):855-63. doi:
10.1111/j.1365-2125.2008.03110.x. [PMID: 18294322] - Devdutt Chaturvedi, Suprabhat Ray, Arvind K Srivastava, Ramesh Chander. Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Bioorganic & medicinal chemistry.
2008 Mar; 16(5):2489-98. doi:
10.1016/j.bmc.2007.11.062. [PMID: 18083521] - Herbert Schuster, Björn Fagerberg, Siôn Edwards, Tamas Halmos, Jerzy Lopatynski, Steen Stender, Grethe Stoa Birketvedt, Serena Tonstad, Ingrid Gause-Nilsson, Sigrún Halldórsdóttir, K Peter Ohman. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Atherosclerosis.
2008 Mar; 197(1):355-62. doi:
10.1016/j.atherosclerosis.2007.05.029. [PMID: 17631296] - Eva Kiss-Tóth, Tamás Roszer. PPARgamma in Kidney Physiology and Pathophysiology.
PPAR research.
2008; 2008(?):183108. doi:
10.1155/2008/183108. [PMID: 19283081] - Martin B Oleksiewicz, Jennifer Southgate, Lars Iversen, Frederikke L Egerod. Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.
PPAR research.
2008; 2008(?):103167. doi:
10.1155/2008/103167. [PMID: 19197366] - Anna C Calkin, Merlin C Thomas. PPAR Agonists and Cardiovascular Disease in Diabetes.
PPAR research.
2008; 2008(?):245410. doi:
10.1155/2008/245410. [PMID: 18288280] - Min-Chul Cho, Kyoung Lee, Sang-Gi Paik, Do-Young Yoon. Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.
PPAR research.
2008; 2008(?):679137. doi:
10.1155/2008/679137. [PMID: 18566691] - Ebele C Chira, Timothy S McMillen, Shari Wang, Antonio Haw, Kevin D O'Brien, Thomas N Wight, Alan Chait. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Atherosclerosis.
2007 Nov; 195(1):100-9. doi:
10.1016/j.atherosclerosis.2006.12.012. [PMID: 17214992] - Harold Bays, Jennifer McElhattan, Brian S Bryzinski. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
Diabetes & vascular disease research.
2007 Sep; 4(3):181-93. doi:
10.3132/dvdr.2007.039. [PMID: 17907108] - John P H Wilding, Ingrid Gause-Nilsson, Anders Persson. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
Diabetes & vascular disease research.
2007 Sep; 4(3):194-203. doi:
10.3132/dvdr.2007.040. [PMID: 17907109] - Serena Tonstad, Kjetil Retterstøl, Leiv Ose, K Peter Ohman, Magnus B Lindberg, Maria Svensson. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Metabolism: clinical and experimental.
2007 Sep; 56(9):1285-92. doi:
10.1016/j.metabol.2007.05.003. [PMID: 17697874] - Bjorn Fagerberg, Herbert Schuster, Grethe Støa Birketvedt, Serena Tonstad, Karl Peter Ohman, Ingrid Gause-Nilsson. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
Diabetes & vascular disease research.
2007 Sep; 4(3):174-80. doi:
10.3132/dvdr.2007.038. [PMID: 17907107] - Robert E Ratner, Shamik Parikh, Conrad Tou. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
Diabetes & vascular disease research.
2007 Sep; 4(3):214-21. doi:
10.3132/dvdr.2007.042. [PMID: 17907111] - Burkhard Göke, Ingrid Gause-Nilsson, Anders Persson. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.
Diabetes & vascular disease research.
2007 Sep; 4(3):204-13. doi:
10.3132/dvdr.2007.041. [PMID: 17907110] - Dae Ryong Cha, Xiaoyan Zhang, Yahua Zhang, Jing Wu, Dongming Su, Jee Young Han, Xuefen Fang, Bo Yu, Matthew D Breyer, Youfei Guan. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Diabetes.
2007 Aug; 56(8):2036-45. doi:
10.2337/db06-1134. [PMID: 17536062] - Hee Oon Han, Seung Hae Kim, Kyoung-Hee Kim, Gwong-Cheung Hur, Hyeon Joo Yim, Hee-Kyung Chung, Sung Ho Woo, Ki Dong Koo, Chang-Seok Lee, Jong Sung Koh, Geun Tae Kim. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
Bioorganic & medicinal chemistry letters.
2007 Feb; 17(4):937-41. doi:
10.1016/j.bmcl.2006.11.050. [PMID: 17157019] - Barry J Goldstein, Julio Rosenstock, Deborah Anzalone, Conrad Tou, K Peter Ohman. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Current medical research and opinion.
2006 Dec; 22(12):2575-90. doi:
10.1185/030079906x154169. [PMID: 17166340] - Catherine Fiévet, Jean-Charles Fruchart, Bart Staels. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Current opinion in pharmacology.
2006 Dec; 6(6):606-14. doi:
10.1016/j.coph.2006.06.009. [PMID: 16973418] - A Susanne M Zadelaar, Lianne S M Boesten, J Wouter Jukema, Bart J M van Vlijmen, Teake Kooistra, Jef J Emeis, Erik Lundholm, German Camejo, Louis M Havekes. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Arteriosclerosis, thrombosis, and vascular biology.
2006 Nov; 26(11):2560-6. doi:
10.1161/01.atv.0000242904.34700.66. [PMID: 16931788] - S Samuelsson, S Johansson, S Halldórsdóttir, H Stenhoff, K P Ohman. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
Journal of clinical pharmacology.
2006 Sep; 46(9):1017-22. doi:
10.1177/0091270006290335. [PMID: 16920896] - Harold Lebovitz. Diabetes: assessing the pipeline.
Atherosclerosis. Supplements.
2006 Apr; 7(1):43-9. doi:
10.1016/j.atherosclerosissup.2006.01.007. [PMID: 16504599] - Sandra L Cox. Tesaglitazar: a promising approach in type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998).
2006 Mar; 42(3):139-46. doi:
10.1358/dot.2006.42.3.937961. [PMID: 16628256] - Nicholas D Oakes, Pia Thalén, Therese Hultstrand, Severina Jacinto, Germán Camejo, Boel Wallin, Bengt Ljung. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
American journal of physiology. Regulatory, integrative and comparative physiology.
2005 Oct; 289(4):R938-46. doi:
10.1152/ajpregu.00252.2005. [PMID: 16183630] - Alexander Tenenbaum, Michael Motro, Enrique Z Fisman. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Cardiovascular diabetology.
2005 Sep; 4(?):14. doi:
10.1186/1475-2840-4-14. [PMID: 16168052] - B Fagerberg, S Edwards, T Halmos, J Lopatynski, H Schuster, S Stender, G Stoa-Birketvedt, S Tonstad, S Halldórsdóttir, I Gause-Nilsson. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Diabetologia.
2005 Sep; 48(9):1716-25. doi:
10.1007/s00125-005-1846-8. [PMID: 16001233] - H Ericsson, B Hamrén, S Bergstrand, M Elebring, L Fryklund, M Heijer, K P Ohman. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2004 Sep; 32(9):923-9. doi:
. [PMID: 15319332] - Henrik Svennberg, Susanne Bergh, Helene Stenhoff. Factorial design for the development of automated solid-phase extraction in the 96-well format for determination of tesaglitazar, in plasma, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2003 Apr; 787(2):231-41. doi:
10.1016/s1570-0232(02)00317-3. [PMID: 12650747] - Bengt Ljung, Krister Bamberg, Björn Dahllöf, Ann Kjellstedt, Nicholas D Oakes, Jörgen Ostling, Lennart Svensson, Germán Camejo. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Journal of lipid research.
2002 Nov; 43(11):1855-63. doi:
10.1194/jlr.m200127-jlr200. [PMID: 12401884] - P Cronet, J F Petersen, R Folmer, N Blomberg, K Sjöblom, U Karlsson, E L Lindstedt, K Bamberg. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.
Structure (London, England : 1993).
2001 Aug; 9(8):699-706. doi:
10.1016/s0969-2126(01)00634-7. [PMID: 11587644]